Three decades of messenger RNA vaccine development
Publication date: Available online 23 August 2019Source: Nano TodayAuthor(s): Rein Verbeke, Ine Lentacker, Stefaan C. De Smedt, Heleen DewitteAbstractIn the early nineties, pioneering steps were taken in the use of mRNA as a therapeutic tool for vaccination. In the following decades, an improved understanding of the mRNA pharmacology, together with novel insights in immunology have positioned mRNA-based technologies as next-generation vaccines. This review outlines the history and current state-of-the-art in mRNA vaccination, while presenting an immunological view on mRNA vaccine development. As such, we highlight the challenges in vaccine design, testing and administration, key considerations in the design of mRNA-based vaccines and new opportunities that arise when packaging mRNA in nanoparticulate vaccines. Finally, we discuss the mRNA self-adjuvant effect as a critical, but dichotomous parameter that determines the safety, efficacy and strength of the evoked immune response.Graphical abstract
Conclusions: The AS04-adjuvanted HPV-16/18 vaccine administered according to a 2-dose schedule to girls 4–6 years of age induced a high and sustained immunologic response with an acceptable safety profile during the 30 months following vaccination.
Conclusions: The PHiD-CV vaccination program in Brazil has resulted in important reductions of pneumococcal disease and substantial cost savings. Instead of switching PCVs, expanding vaccine coverage or investing in other health care interventions would be a more efficient use of resources to improve the health of the population in Brazil.
No abstract available
Hopes for a genital herpes vaccine have been raised by a trial treatment that stops genital lesions and low-lying infections in guinea pigs and mice
The order creates a new task force charged with coming up with a 5-year plan.Medscape Medical News
Condition: Flu, Human Intervention: Behavioral: Brief educational intervention Sponsor: Agrupamento de Centros de Saúde de Dão Lafões Not yet recruiting
Conditions: Uterine Cervical Neoplasms; Cervical Cancer; Cervical Neoplasms; Cervix Cancer Interventions: Drug: Sintilimab; Drug: quadrivalent HPV vaccine Sponsors: Buhai Wang; Innovent Biologics (Suzhou) Co. Ltd. Recruiting
Conditions: Virtual Reality; Vaccination; Pain; Nursing Intervention: Other: Virtual Reality Group Sponsor: Cardenal Herrera University Not yet recruiting